drugset / Trial / NCT03610971
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
Phase 2
Active not recruiting
24 enrolled
H. Lee Moffitt Cancer Center and Research Institute
H. Jean Khoury Cure CML Consortium · collabIncyte Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if adding Ruxolitinib to a Tyrone Kinase Inhibitor (TKI), prior to a second attempt at stopping a TKI will lead to prolonged treatment free remission (TFR).
Timeline
- Start
- 2019-11-19
- Primary completion
- 2025-09-25
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bosutinib | Small molecule | — | — |
| Subject | Imatinib | Small molecule | — | — |
| Subject | Nilotinib | Small molecule | — | — |
| Subject | Ruxolitinib | Small molecule | 15 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | — | — |